MIRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Mirum Pharmaceuticals Inc (MIRM) does not present a compelling buy opportunity for a beginner investor with a long-term focus at this moment. While the company shows strong revenue growth and positive analyst sentiment, insider selling, declining net income, and lack of immediate catalysts make it prudent to hold off on investing for now.
The technical indicators are neutral to slightly bearish. The MACD is below zero and negatively contracting, RSI is neutral at 42.904, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 86.293), with resistance at 90.767, indicating limited upside in the short term.
Analysts have consistently raised price targets, with multiple firms projecting significant upside (e.g., RBC Capital at $128, Morgan Stanley at $130).
Strong revenue growth in Q4 2025 (+49.81% YoY) and an 81.02% gross margin suggest robust operational performance.
Upcoming pivotal readouts in key therapeutic areas could unlock long-term value.
Insider selling has increased significantly (+377.70% last month), which could indicate a lack of confidence from those closest to the company.
Net income and EPS have declined sharply (-75.91% and -77.55% YoY, respectively), raising concerns about profitability.
No recent news or significant catalysts in the short term to drive immediate price appreciation.
In Q4 2025, revenue grew by 49.81% YoY to $148.93M, and gross margin improved to 81.02% (+5.10% YoY). However, net income dropped significantly to -$5.73M (-75.91% YoY), and EPS fell to -$0.11 (-77.55% YoY), indicating profitability challenges despite strong revenue growth.
Analysts are overwhelmingly positive, with multiple firms maintaining Buy or Outperform ratings and raising price targets (e.g., Evercore ISI to $126, Stifel to $125, Morgan Stanley to $130). Analysts highlight strong commercial momentum, durable revenue growth, and upcoming catalysts as key drivers for long-term value.
